This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Through the Sehat Sathi App business can access unsecured business loans at low interest
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
The company reports revenue growth of 26% and PAT growth of 21% YoY
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Demand normalisation post the second wave contributed to the steady growth
Subscribe To Our Newsletter & Stay Updated
